CK2-TN03

Overview

CK2-TN03 is an ATP-competitive casein kinase 2 ( CK2 ) inhibitor, with an IC 50 of 165 nM and a K i of 20 nM. CK2-TN03 inhibits CK2-mediated survivin activation and reduces CK2-dependent phosphorylation levels of BRD4/MYCN and AKT1 . CK2-TN03 exerts anti-neuroblastoma effects by inhibiting survivin , leading to mitotic catastrophe and apoptosis of cancer cells. CK2-TN03 can be used in studies related to neuroblastoma.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > CNS Neoplasm | Products > Disease Areas > Glioma | Products > Disease Areas > Glioblastoma | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Research Areas > Neurological Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Akt | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Caspase | Products > Signaling Pathways > MDM-2/p53 | Products > Signaling Pathways > Casein Kinase | Products > Signaling Pathways > Survivin | Products > Signaling Pathways > Epigenetic Reader Domain

Product Information

• Catalog No.: HY-181442
• CAS No.: 313226-24-3
• Molecular Formula: C17H14N2O3S
• Molecular Weight: 326.37
• Purity: 98.02%
• Storage: Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Availability: In-stock

Source

Original product source